Weight Regain After GLP-1: Why It Can Happen After Stopping Treatment
Weight regain after GLP-1-based treatment is a common concern, especially when people have seen meaningful progress during doctor-supervised care. In clinical practice, this does not usually mean a person has “failed” treatment. More often, it reflects the fact that obesity is a chronic condition shaped by appetite signalling, energy expenditure, and long-term metabolic regulation. In Singapore, Mounjaro (tirzepatide) is a prescription-only medicine and should be used under medical supervision rather than treated as a short-term standalone fix (HSA, 2023).
Key Takeaways
Weight regain after GLP-1 treatment can happen because the biological drivers of hunger and weight regulation often return once treatment is stopped.
Tirzepatide works on both GIP and GLP-1 receptors, which helps influence appetite, insulin secretion, and glucagon signalling while treatment continues.
In the SURMOUNT-4 trial, people who stopped tirzepatide after an initial treatment phase regained substantially more weight than those who continued treatment.
Weight regain is not only about appetite. Lower energy expenditure after weight loss can also make weight maintenance harder.
Lifestyle measures remain important, but for some patients, they may not fully offset the biological pressure to regain weight after medication withdrawal.
In Singapore, decisions about starting, continuing, pausing, or restarting Mounjaro should be made with a doctor who can review risks, indications, side effects, and longer-term treatment goals.
What “weight regain after GLP-1” usually means
When people talk about weight regain after GLP-1 treatment, they usually mean some increase in body weight after stopping medicines that had been helping reduce appetite and support lower calorie intake. This can happen after GLP-1 receptor agonists more broadly, and similar patterns have also been observed after stopping tirzepatide, which is a dual GIP and GLP-1 receptor agonist.
It is important to frame this properly. Weight regain does not necessarily mean all benefits disappear immediately, and it does not mean the earlier treatment was pointless. Rather, it suggests that the physiology contributing to weight gain can re-emerge when pharmacologic support is withdrawn. Clinical trial data and review literature both support that substantial regain is common after discontinuation of anti-obesity pharmacotherapy (JAMA Network).
How tirzepatide affects appetite and metabolic regulation
Dual GIP and GLP-1 receptor activity
Tirzepatide is not a standard single-pathway GLP-1 medicine. It activates both the GIP receptor and the GLP-1 receptor. According to official prescribing information, it enhances first- and second-phase insulin secretion and reduces glucagon levels in a glucose-dependent manner. These pathways are relevant to glycaemic control, but they also intersect with satiety and food intake regulation.
Appetite reduction while treatment continues
GLP-1-based treatment helps many patients feel fuller sooner, eat less, and experience less persistent hunger. This appetite effect is one reason weight reduction can occur during treatment. When the medicine is withdrawn, that appetite suppression may fade, and the person can experience a return of stronger hunger signals, more food preoccupation, or reduced fullness after meals.
Why weight regain can happen after stopping treatment
The body defends against weight loss
Body weight is not regulated by willpower alone. Modern obesity physiology describes a system in which energy intake, energy expenditure, neuroendocrine signalling, and reward pathways interact to defend body weight. After weight loss, the body may respond in ways that promote regain, including increased hunger and lower energy expenditure (National Library of Medicine).
Appetite often rises again
Once a GLP-1-based medicine is stopped, the treatment effect that had been dampening hunger is reduced or removed. For some people, this means appetite returns quickly. In practical terms, it can feel like meals are less filling, cravings are stronger, and the mental effort needed to maintain the same eating pattern becomes much greater (JAMA Network).
Energy expenditure may stay lower after weight loss
Weight maintenance can also become harder because the body may burn fewer calories after weight loss than expected for the new body size, a phenomenon often described as adaptive thermogenesis. This does not make regaining inevitable, but it can make the same habits less effective than they were earlier in treatment (National Library of Medicine).
Lifestyle support may help, but may not fully replace the effects
Nutrition quality, protein intake, physical activity, resistance training, sleep, and behavioural support all matter. However, newer evidence suggests that discontinuation-related regain can still occur despite lifestyle measures, which is one reason obesity medicine is increasingly approached as long-term chronic disease care rather than a temporary intervention alone.
What the SURMOUNT-4 trial showed after tirzepatide withdrawal
The clearest trial example comes from SURMOUNT-4. In that study, adults with obesity or overweight first received open-label tirzepatide for 36 weeks. Those who reached the maximum tolerated dose were then randomised either to continue tirzepatide or switch to placebo for another 52 weeks.
Participants who completed the 36-week lead-in had already achieved a mean weight reduction of 20.9% at the point of randomisation. From week 36 to week 88, mean weight changed by -5.5% in those who continued tirzepatide but increased by 14.0% in those switched to placebo. Overall mean weight reduction from week 0 to week 88 was 25.3% with continued tirzepatide versus 9.9% after switching to placebo (JAMA Network).
The trial also found that 89.5% of participants continuing tirzepatide maintained at least 80% of the weight they had lost during the lead-in phase, compared with 16.6% in the placebo group. JAMA’s discussion of the results noted that much of the initial improvement in cardiometabolic risk factors was reversed after withdrawal.
This does not mean every person will regain weight in the same way or at the same speed. It does mean that the regain after stopping treatment is biologically plausible, clinically observed, and supported by trial data rather than being a rare exception.
Why this matters for Mounjaro care in Singapore
In Singapore, HSA records show Mounjaro has been approved locally, and HSA materials classify it as a prescription-only medicine. That matters because treatment decisions should sit within a medical review of indication, expected benefits, side effects, contraindications, and long-term planning.
Doctor supervision is especially important when a patient is thinking about stopping treatment because the question is usually bigger than the medication itself. A clinician may need to assess whether the original drivers of weight gain are still active, whether appetite has returned, whether glycaemic factors are relevant, and whether a maintenance strategy is in place.
Clinical reasons someone may stop GLP-1 or tirzepatide treatment
People may stop treatment for several reasons, including side effects, cost, access issues, treatment fatigue, pregnancy planning, intercurrent illness, or the assumption that weight loss can now be maintained without medication. Some discontinuations are clinician-directed, while others happen abruptly. The reason for stopping can affect what happens next and what kind of follow-up is needed (JAMA Network).
For Mounjaro specifically, official prescribing information includes important precautions and contraindications, including a boxed warning regarding thyroid C-cell tumours in rodents and a contraindication in people with a personal or family history of medullary thyroid carcinoma or MEN2. The product information also notes that it has not been studied in patients with a history of pancreatitis and is not indicated for type 1 diabetes.
How clinicians try to reduce the risk of regaining
Setting expectations early
One of the most useful parts of obesity treatment is expectation setting. If a patient views treatment as a short course with a fixed finish line, they may be caught off guard by rebound hunger or gradual regain. Framing obesity as a chronic disease helps patients understand why maintenance planning matters.
Building a maintenance plan before stopping
When treatment is likely to be paused or stopped, clinicians often review practical areas such as meal structure, protein adequacy, resistance training, sleep, appetite awareness, and frequency of weight monitoring. These strategies are not substitutes for medical advice, but they can support transition planning. Evidence suggests lifestyle support remains valuable even though it may not completely prevent regain for everyone.
Monitoring after discontinuation
Follow-up matters because recovery can be gradual at first. Early review allows the clinician to assess appetite changes, changes in eating patterns, loss of routine, reduced activity, or deterioration in glucose-related markers where relevant. This is one reason stopping and restarting should not be treated casually in a self-directed fashion.
Takeaway
Weight regain after GLP-1 treatment can happen because the biology that influences hunger, satiety, and energy expenditure often persists after the medicine is stopped. Trial data with tirzepatide show that continued treatment supports weight maintenance more effectively than withdrawal, and obesity medicine literature increasingly treats this as a chronic disease issue rather than a simple lapse in discipline.
In Singapore, Mounjaro remains a prescription-only medicine, so decisions about stopping or continuing treatment should be made within doctor-supervised care.
To better understand how GLP-1 and GIP treatments are used, what to expect over time, and how care is structured locally, you can refer to our What You Need to Know About Mounjaro Medications in Singapore.
FAQ
Is weight regain after GLP-1 treatment common?
It can be common, especially after treatment is stopped. Clinical trial and review data show that many patients regain at least some weight after discontinuation, although the degree varies between individuals.
Does stopping Mounjaro mean all weight will come back?
Not always, but substantial regain can occur. In SURMOUNT-4, people who switched from tirzepatide to placebo regained significantly more weight than those who stayed on treatment, though individual outcomes differed.
Why does appetite seem to come back after stopping?
Because the medication effect that was helping reduce hunger and support satiety no longer continues in the same way. Once that pharmacologic support is removed, underlying appetite signals may become more noticeable again.
Can lifestyle changes alone prevent the regain?
Lifestyle measures are still important, but they may not fully counter the biological pressures that follow weight loss and medication withdrawal. That is why maintenance planning often needs a broader medical strategy.
Is Mounjaro available in Singapore without a prescription?
No. HSA materials list Mounjaro as a prescription-only medicine in Singapore.